Patient characteristics of TCL (N = 16)
| Characteristic . | Total (N = 16) Number (%) . |
|---|---|
| Age (median, range) | 60 y (35-81) |
| Gender, male | 13 (81%) |
| Years from diagnosis to registration | |
| Median, range | 3.5 (1.0-20.4) |
| Ann Arbor stage for PTCL patients | |
| 2 | 1 (11%) |
| 4 | 8 (89%) |
| ISCL/EORTC stage for CTCL patients | |
| IIB | 6 (86%) |
| III | 1 (14%) |
| Performance score | |
| 0 | 4 (25%) |
| 1 | 11 (69%) |
| 2 | 1 (6%) |
| No. previous treatments (median, range) | 3 (1-11) |
| Prior stem cell transplant | 5 (31%) |
| Type of TCL | |
| CTCL (mycosis fungoides) | 7 (44%) |
| Peripheral TCL, unspecified | 4 (25%) |
| Anaplastic large cell lymphoma (systemic type) | 2 (13%) |
| Angioimmunoblastic TCL | 1 (6%) |
| Extranodal natural killer/TCL, nasal-type | 1 (6%) |
| Precursor T-lymphoblastic leukemia/lymphoma | 1 (6%) |
| Characteristic . | Total (N = 16) Number (%) . |
|---|---|
| Age (median, range) | 60 y (35-81) |
| Gender, male | 13 (81%) |
| Years from diagnosis to registration | |
| Median, range | 3.5 (1.0-20.4) |
| Ann Arbor stage for PTCL patients | |
| 2 | 1 (11%) |
| 4 | 8 (89%) |
| ISCL/EORTC stage for CTCL patients | |
| IIB | 6 (86%) |
| III | 1 (14%) |
| Performance score | |
| 0 | 4 (25%) |
| 1 | 11 (69%) |
| 2 | 1 (6%) |
| No. previous treatments (median, range) | 3 (1-11) |
| Prior stem cell transplant | 5 (31%) |
| Type of TCL | |
| CTCL (mycosis fungoides) | 7 (44%) |
| Peripheral TCL, unspecified | 4 (25%) |
| Anaplastic large cell lymphoma (systemic type) | 2 (13%) |
| Angioimmunoblastic TCL | 1 (6%) |
| Extranodal natural killer/TCL, nasal-type | 1 (6%) |
| Precursor T-lymphoblastic leukemia/lymphoma | 1 (6%) |